BRPI1010261A2 - agente e método de formação de imagem in vivo, composto precursos, métodos para a preparação de um composto precursor e do agente de formação de imagem in vivo, e para diagnostico de uma condição, kit, cassete,e , composição radiofarmaceutica. - Google Patents
agente e método de formação de imagem in vivo, composto precursos, métodos para a preparação de um composto precursor e do agente de formação de imagem in vivo, e para diagnostico de uma condição, kit, cassete,e , composição radiofarmaceutica.Info
- Publication number
- BRPI1010261A2 BRPI1010261A2 BRPI1010261A BRPI1010261A BRPI1010261A2 BR PI1010261 A2 BRPI1010261 A2 BR PI1010261A2 BR PI1010261 A BRPI1010261 A BR PI1010261A BR PI1010261 A BRPI1010261 A BR PI1010261A BR PI1010261 A2 BRPI1010261 A2 BR PI1010261A2
- Authority
- BR
- Brazil
- Prior art keywords
- precursor compound
- imaging agent
- vivo imaging
- diagnosing
- cassette
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16413109P | 2009-03-27 | 2009-03-27 | |
| GBGB0905328.1A GB0905328D0 (en) | 2009-03-27 | 2009-03-27 | Indole derivatives |
| PCT/EP2010/053998 WO2010109007A2 (en) | 2009-03-27 | 2010-03-26 | Indole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1010261A2 true BRPI1010261A2 (pt) | 2016-03-22 |
Family
ID=40671850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1010261A BRPI1010261A2 (pt) | 2009-03-27 | 2010-03-26 | agente e método de formação de imagem in vivo, composto precursos, métodos para a preparação de um composto precursor e do agente de formação de imagem in vivo, e para diagnostico de uma condição, kit, cassete,e , composição radiofarmaceutica. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8790619B2 (enExample) |
| EP (1) | EP2411362B1 (enExample) |
| JP (1) | JP5651163B2 (enExample) |
| KR (1) | KR101692090B1 (enExample) |
| CN (1) | CN102448933B (enExample) |
| AU (1) | AU2010227527B2 (enExample) |
| BR (1) | BRPI1010261A2 (enExample) |
| CA (1) | CA2756887C (enExample) |
| ES (1) | ES2635310T3 (enExample) |
| GB (1) | GB0905328D0 (enExample) |
| IL (1) | IL215019A0 (enExample) |
| MX (1) | MX2011010154A (enExample) |
| NZ (1) | NZ595227A (enExample) |
| RU (1) | RU2525196C2 (enExample) |
| SG (1) | SG174589A1 (enExample) |
| WO (1) | WO2010109007A2 (enExample) |
| ZA (1) | ZA201106708B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0905328D0 (en) | 2009-03-27 | 2009-05-13 | Ge Healthcare Ltd | Indole derivatives |
| EP2552891B1 (en) * | 2010-03-26 | 2018-08-08 | GE Healthcare Limited | Tricyclic indole derivatives as pbr ligands |
| GB201016038D0 (en) * | 2010-09-24 | 2010-11-10 | Ge Healthcare Ltd | In vivo imaging method |
| GB201016411D0 (en) * | 2010-09-30 | 2010-11-10 | Ge Healthcare Ltd | In vivo imaging method for cancer |
| GB201021263D0 (en) * | 2010-12-15 | 2011-01-26 | Ge Healthcare Ltd | Solid phase extraction method |
| EP2694505B1 (en) * | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| EP2718464A1 (en) | 2011-06-06 | 2014-04-16 | Imperial Innovations Limited | Methods to predict binding affinity of tspo imaging agents to tspo |
| ES2562656T3 (es) * | 2011-09-30 | 2016-03-07 | Ge Healthcare Limited | Sistemas de calibración y normalización y métodos para sintetizadores radiofarmacéuticos |
| WO2014083163A1 (en) | 2012-11-30 | 2014-06-05 | Ge Healthcare Limited | Zinc halide mediated cyclization process leading to tricyclic indoles |
| CN111362863A (zh) * | 2012-11-30 | 2020-07-03 | 通用电气健康护理有限公司 | 三环吲哚衍生物的结晶方法 |
| GB201312768D0 (en) * | 2013-07-17 | 2013-08-28 | Ge Healthcare Ltd | Work-up procedure |
| GB201316766D0 (en) * | 2013-09-20 | 2013-11-06 | Ge Healthcare Uk Ltd | Macrophage Imaging |
| GB201316764D0 (en) * | 2013-09-20 | 2013-11-06 | Ge Healthcare Ltd | Novel compounds |
| GB201316762D0 (en) * | 2013-09-20 | 2013-11-06 | Ge Healthcare Ltd | Novel compounds |
| WO2016087653A1 (en) | 2014-12-04 | 2016-06-09 | Ge Healthcare Limited | Method of removing acetaldehyde from radioactive pharmaceuticals |
| CN106748802B (zh) * | 2016-12-26 | 2018-11-13 | 南京理工大学 | 一种制备含氟仲胺的方法 |
| CN110997068B (zh) * | 2017-05-24 | 2022-12-06 | 宾夕法尼亚大学董事会 | 用于成像和放射疗法的经放射标记的荧光parp抑制剂 |
| US11200669B2 (en) * | 2019-11-19 | 2021-12-14 | Uih America, Inc. | Systems and methods for determining plasma input function used in positron emission tomography imaging |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3939177A (en) * | 1972-11-22 | 1976-02-17 | Sterling Drug Inc. | 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles |
| US3979391A (en) * | 1972-11-22 | 1976-09-07 | Sterling Drug Inc. | 1,2,3,4-Tetrahydrocarbazoles |
| FR2599740B1 (fr) * | 1986-06-05 | 1988-08-12 | Rhone Poulenc Sante | Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant |
| US5270030A (en) * | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| EP1043991A4 (en) | 1997-11-14 | 2005-02-02 | Lilly Co Eli | TREATMENT OF ALZHEIMER DISEASE |
| US6281355B1 (en) * | 1997-12-03 | 2001-08-28 | Taisho Pharmaceutical Co., Ltd. | Nitrogen-containing tetracyclic compounds |
| JPH11228539A (ja) * | 1997-12-03 | 1999-08-24 | Taisho Pharmaceut Co Ltd | 含窒素四環性化合物 |
| MXPA01005905A (es) * | 1998-12-11 | 2002-09-18 | Univ Virginia Commonwealth | Ligandos selectivos de receptores de 5-ht6. |
| FR2788776B1 (fr) | 1999-01-26 | 2001-02-23 | Synthelabo | Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique |
| GB0115927D0 (en) | 2001-06-29 | 2001-08-22 | Nycomed Amersham Plc | Solid-phase nucleophilic fluorination |
| GB0115929D0 (en) | 2001-06-29 | 2001-08-22 | Nycomed Amersham Plc | Solid-phase electrophilic fluorination |
| JP2005527464A (ja) | 2001-08-09 | 2005-09-15 | イーライ・リリー・アンド・カンパニー | ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体 |
| ES2252497T3 (es) | 2001-08-09 | 2006-05-16 | Eli Lilly And Company | Derivados ciclohept(b)indol como inhibidores de spla2. |
| GB0523506D0 (en) * | 2005-11-18 | 2005-12-28 | Hammersmith Imanet Ltd | Novel in vivo imaging compounds |
| GB0905328D0 (en) | 2009-03-27 | 2009-05-13 | Ge Healthcare Ltd | Indole derivatives |
-
2009
- 2009-03-27 GB GBGB0905328.1A patent/GB0905328D0/en not_active Ceased
-
2010
- 2010-03-26 RU RU2011138850/04A patent/RU2525196C2/ru active
- 2010-03-26 BR BRPI1010261A patent/BRPI1010261A2/pt not_active Application Discontinuation
- 2010-03-26 WO PCT/EP2010/053998 patent/WO2010109007A2/en not_active Ceased
- 2010-03-26 CA CA2756887A patent/CA2756887C/en active Active
- 2010-03-26 SG SG2011070018A patent/SG174589A1/en unknown
- 2010-03-26 US US13/258,465 patent/US8790619B2/en active Active
- 2010-03-26 JP JP2012501315A patent/JP5651163B2/ja active Active
- 2010-03-26 NZ NZ595227A patent/NZ595227A/xx unknown
- 2010-03-26 KR KR1020117025305A patent/KR101692090B1/ko active Active
- 2010-03-26 EP EP10710356.6A patent/EP2411362B1/en active Active
- 2010-03-26 ES ES10710356.6T patent/ES2635310T3/es active Active
- 2010-03-26 CN CN201080023868.3A patent/CN102448933B/zh active Active
- 2010-03-26 AU AU2010227527A patent/AU2010227527B2/en active Active
- 2010-03-26 MX MX2011010154A patent/MX2011010154A/es active IP Right Grant
- 2010-09-13 US US12/880,218 patent/US8501153B2/en active Active
-
2011
- 2011-09-07 IL IL215019A patent/IL215019A0/en not_active IP Right Cessation
- 2011-09-13 ZA ZA2011/06708A patent/ZA201106708B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101692090B1 (ko) | 2017-01-02 |
| AU2010227527A1 (en) | 2011-10-13 |
| RU2011138850A (ru) | 2013-05-10 |
| US20110070161A1 (en) | 2011-03-24 |
| WO2010109007A3 (en) | 2010-11-25 |
| EP2411362A2 (en) | 2012-02-01 |
| JP2012521973A (ja) | 2012-09-20 |
| ZA201106708B (en) | 2013-02-27 |
| JP5651163B2 (ja) | 2015-01-07 |
| AU2010227527B2 (en) | 2015-03-12 |
| GB0905328D0 (en) | 2009-05-13 |
| IL215019A0 (en) | 2011-11-30 |
| CN102448933B (zh) | 2014-07-02 |
| NZ595227A (en) | 2013-11-29 |
| RU2525196C2 (ru) | 2014-08-10 |
| US20120020884A1 (en) | 2012-01-26 |
| ES2635310T3 (es) | 2017-10-03 |
| CN102448933A (zh) | 2012-05-09 |
| US8501153B2 (en) | 2013-08-06 |
| HK1167393A1 (en) | 2012-11-30 |
| EP2411362B1 (en) | 2017-05-31 |
| WO2010109007A2 (en) | 2010-09-30 |
| US8790619B2 (en) | 2014-07-29 |
| SG174589A1 (en) | 2011-10-28 |
| CA2756887A1 (en) | 2010-09-30 |
| CA2756887C (en) | 2018-06-19 |
| KR20110133492A (ko) | 2011-12-12 |
| MX2011010154A (es) | 2011-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1010261A2 (pt) | agente e método de formação de imagem in vivo, composto precursos, métodos para a preparação de um composto precursor e do agente de formação de imagem in vivo, e para diagnostico de uma condição, kit, cassete,e , composição radiofarmaceutica. | |
| BRPI0919551A2 (pt) | agente e método de formação de imagem in vivo, composto precursor, kit, cassete, composição radiofarmacêutica, e, métodos para a preparação do agente de formação de imagem in vivo, e para diagnóstico de uma condição | |
| BRPI0814811A2 (pt) | Composto, agente, método, e composição de diagnóstico, uso de um composto, e, método de formação de imagem | |
| IL211526A0 (en) | Compounds and methods for 18f labeled agents, compositions comprising such compounds and their use for diagnostic imaging | |
| ZA201004112B (en) | Non-destructive testing,in particular for tubes during manufacture or in the finished state | |
| GB0716885D0 (en) | Diagnostic agent | |
| BRPI0822885A2 (pt) | Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral | |
| IL195271A0 (en) | Composition for diagnosing amyloid-related disease | |
| BRPI0912384A2 (pt) | composição, e, método para preparar uma composição | |
| BRPI0908092A2 (pt) | Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante | |
| ZA201108562B (en) | A system,method,and luminescent marker for improved diffuse luminescent imaging or tomography in scattering media | |
| EP2185730A4 (en) | METHOD AND COMPOSITIONS FOR SICKNESS DIAGNOSIS | |
| BRPI0910072A2 (pt) | composto, composição farmaceutic, e, método para prover anestesia a um mamífero. | |
| PT2530093T (pt) | Composto de indocianina, método de síntese do mesmo, método de purificação do mesmo, composição de diagnóstico utilizando o composto de indocianina, e dispositivo para medição da cinética in vivo e dispositivo para visualização da circulação utilizando a composição de diagnóstico | |
| BR112013013285A2 (pt) | agente de formação de imagem, precursor, métodos de preparação do agente de formação de imagem, e de formação de imagem, composição radiofarmacêutica, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem | |
| BRPI1007487A2 (pt) | composição para radiomarcar ácido dietilenotriaminopentacético (dtpa)-dextrano | |
| CL2013000483A1 (es) | Agente de formación de imagen que comprende un péptido cíclico de enlace c-met radioetiquetado por 18f; composicion de agente de formación de imagen; precursor util en la formación del péptido cíclico; método para la preparacion del peptido cíclico. | |
| GB0815846D0 (en) | diagnosis, prognosis and imaging of disease | |
| EP2253748A4 (en) | MONOFILAMENT FOR X-RAY CONTRAST RADIOGRAPHY | |
| EP2257316A4 (en) | CONTRASTANT, METHOD FOR THE PRODUCTION OF CONTRASTING AGENTS AND ILLUSTRATIVE PROCESS | |
| WO2007148083A3 (en) | Stabilisation of radiopharmaceutical precursors | |
| PL2151328T3 (pl) | Folia, sposób jej wytwarzania i zastosowanie | |
| IL218456A (en) | Diagnostic Composition Containing Bite History (2,4,6 - Triodophenyl) and Methods for Diagnosis and Imaging | |
| IL209243A (en) | Preparations suitable for giving, using them and methods for obtaining a diagnostic image | |
| WO2011146390A3 (en) | Compositions and methods for in vivo imaging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |